VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

BOPA 2018 | The switch to biosimilar rituximab at UCH: 12 months on

At the 2018 British Oncology Pharmacy Association (BOPA) Annual Symposium, Simon Cheesman, MRPharmS, of University College London, London, UK, presented the experiences at University College Hospital London of making the switch to biosimilar rituximab for the treatment of selected patients receiving treatment for follicular lymphoma. One year on, we are joined by Mr Cheesman at the 2018 BOPA Annual Symposium in Birmingham, UK, to hear how this switch has impacted patients responses and treatment costs over the past 12 months.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter